Compare First Trust Cloud Computing ETF (SKYY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs Summit Therapeutics Inc — how do they compare? First Trust Cloud Computing ETF trades at $174.78 (market cap $3.47B), while Summit Therapeutics Inc trades at $17.54 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 4× First Trust Cloud Computing ETF's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 85 Days and Summit Therapeutics Inc for 16 Days on average.
| SKYY | SMMT | |
|---|---|---|
Market Cap | $3.47B | $13.71B |
Volume | 176,159 | 6,173,057 |
52-Week High | $171.01 | $26.38 |
52-Week Low | $104.16 | $12.43 |
Typical Hold Time | 85 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Trust Cloud Computing ETF (SKYY) trades at $174.09, up 1.94% with bullish technical signals from moving averages. The ETF recently hit a new 52-week high, reflecting strong momentum in cloud computing stocks driven by AI infrastructure demand. Technical indicators show support at $169 and resistance at $171-173, with the current price near recent highs.
SKYY offers diversified exposure to cloud infrastructure and software companies benefiting from secular trends in AI adoption and digital transformation. Key risks include sector concentration and market volatility, while institutional sentiment remains positive given the long-term growth prospects in cloud computing.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
